Cargando…

Increased COUP-TFII expression in adult hearts induces mitochondrial dysfunction resulting in heart failure

Mitochondrial dysfunction and metabolic remodelling are pivotal in the development of cardiomyopathy. Here, we show that myocardial COUP-TFII overexpression causes heart failure in mice, suggesting a causal effect of elevated COUP-TFII levels on development of dilated cardiomyopathy. COUP-TFII repre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, San-Pin, Kao, Chung-Yang, Wang, Leiming, Creighton, Chad J., Yang, Jin, Donti, Taraka R., Harmancey, Romain, Vasquez, Hernan G., Graham, Brett H., Bellen, Hugo J., Taegtmeyer, Heinrich, Chang, Ching-Pin, Tsai, Ming-Jer, Tsai, Sophia Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568566/
https://www.ncbi.nlm.nih.gov/pubmed/26356605
http://dx.doi.org/10.1038/ncomms9245
Descripción
Sumario:Mitochondrial dysfunction and metabolic remodelling are pivotal in the development of cardiomyopathy. Here, we show that myocardial COUP-TFII overexpression causes heart failure in mice, suggesting a causal effect of elevated COUP-TFII levels on development of dilated cardiomyopathy. COUP-TFII represses genes critical for mitochondrial electron transport chain enzyme activity, oxidative stress detoxification and mitochondrial dynamics, resulting in increased levels of reactive oxygen species and lower rates of oxygen consumption in mitochondria. COUP-TFII also suppresses the metabolic regulator PGC-1 network and decreases the expression of key glucose and lipid utilization genes, leading to a reduction in both glucose and oleate oxidation in the hearts. These data suggest that COUP-TFII affects mitochondrial function, impairs metabolic remodelling and has a key role in dilated cardiomyopathy. Last, COUP-TFII haploinsufficiency attenuates the progression of cardiac dilation and improves survival in a calcineurin transgenic mouse model, indicating that COUP-TFII may serve as a therapeutic target for the treatment of dilated cardiomyopathy.